San Francisco, CA, United States of America

Javier Szwarcberg

This inventor holds 11 USPTO granted patents and 17 published patent applications, plus 3 CIPO patents and 7 EPO patents. Top assignee: Intermune, Inc.. Active years: 2009-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Javier Szwarcberg. Retrieved from https://idiyas.com/inventor/javier-szwarcberg

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 (Patent Applications = 17)

% Patents Active = 100.0

CIPO Patents = 3

EPO Patents = 7 (Patent Applications = 10)

Average Co-Inventor Count = 2.0

ph-index = 6

Forward Citations = 74(Granted Patents)

Location History:

San Mateo, CA (US) (2009)
San Francisco, CA (US) (2009 - 2014)

Company Filing History:

11 out of 52

Intermune, Inc.

patents

Years Active: 2009-2014

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8754109 - Pirfenidone therapy and inducers of cytochrome P450 (2014-06-17),

2. 8648098 - Pirfenidone therapy and inducers of cytochrome P450 (2014-02-11),

3. 8609701 - Pirfenidone treatment for patients with atypical liver function (2013-12-17),

4. 8592462 - Pirfenidone treatment for patients with atypical liver function (2013-11-26),

5. 8318780 - Methods of administering pirfenidone therapy (2012-11-27),

6. 8084475 - Pirfenidone therapy and inducers of cytochrome P450 (2011-12-27),

7. 8013002 - Methods of administering pirfenidone therapy (2011-09-06),

8. 7910610 - Methods of administering pirfenidone therapy (2011-03-22),

9. 7816383 - Methods of administering pirfenidone therapy (2010-10-19),

10. 7635707 - Pirfenidone treatment for patients with atypical liver function (2009-12-22),

11. 7566729 - Modifying pirfenidone treatment for patients with atypical liver function (2009-07-28),

Title: Innovator Spotlight: Javier Szwarcberg

Introduction: Javier Szwarcberg is a prominent inventor based in San Francisco, California, known for his significant contributions to pharmaceutical innovations. With a total of 11 patents to his name, Szwarcberg focuses on developing therapies that enhance patient care and safety in drug administration.

Latest Patents: Among his latest innovations, Szwarcberg has developed patents related to Pirfenidone therapy and inducers of cytochrome P450. His work encompasses methods aimed at avoiding adverse drug interactions with Pirfenidone and CYP inducers, which can include substances such as smoking. These inventions represent a critical advancement in the field of pharmacology, ensuring better treatment outcomes for patients requiring Pirfenidone.

Career Highlights: Szwarcberg’s career is marked by his dedication to advancing medical technology and improving therapeutic methods. Currently affiliated with Intermune, Inc., he has been instrumental in driving innovation within the company, contributing to the development of new drugs that enhance treatment efficacy.

Collaborations: Alongside his colleague, Williamson Ziegler Bradford, Szwarcberg has collaborated on various research initiatives. Their teamwork reflects a commitment to pioneering methods in drug therapy and improving healthcare practices within the industry.

Conclusion: Javier Szwarcberg’s work exemplifies the spirit of innovation within the pharmaceutical sector. His patents not only enhance our understanding of drug interactions but also pave the way for safer treatment protocols for patients. As he continues to innovate, the potential impact of his discoveries promises to make significant strides in medical science.

Profile summary based on public USPTO records.